Daftar Isi:
  • Portal hypertension is a clinical syndrome characterized by pathological elevation of portal venous pressure and all its consequences. In portal hypertension, there is an increase in pressure in the veins that carry blood from the splanchnic organs to the liver. The main factors of portal hypertension include increased intrahepatic resistance to portal blood flow due to degenerative nodules and increased splanchnic blood flow secondary to vasodilation in the splanchnic vascular bed. Clinical symptoms indicated in portal hypertension are varicella hemorrhage with hematemesis or vomiting of blood (vomitus may be red blood mixed with clumps or coffee grounds), and/or melena, i.e. red or black defecation-like petis (shrimp paste). The goal of treatment of patients with portal hypertension is to reduce portal pressure. Drugs for portal hypertension should be able to lower blood vessel portal pressure without lowering arterial pressure, which may aggravate hyperdynamic circulation and incre ase the risk of renal failure. Most of the drugs often used in clinical practice are splanchnic vascular vasoconstrictors vasopressin derivatives (terlipressin), somatostatin, somatostatin analogs (octreotide and vapreotide), Nonselective β-Blocker and Carvedilol.